268 related articles for article (PubMed ID: 30386953)
1. Extracellular vesicles of multiple myeloma cells utilize the proteasome inhibitor mechanism to moderate endothelial angiogenesis.
Zarfati M; Avivi I; Brenner B; Katz T; Aharon A
Angiogenesis; 2019 Feb; 22(1):185-196. PubMed ID: 30386953
[TBL] [Abstract][Full Text] [Related]
2. Microvesicles shed from bortezomib-treated or lenalidomide-treated human myeloma cells inhibit angiogenesis in vitro.
Guo HM; Sun L; Yang L; Liu XJ; Nie ZY; Luo JM
Oncol Rep; 2018 Jun; 39(6):2873-2880. PubMed ID: 29693175
[TBL] [Abstract][Full Text] [Related]
3. PO-45 - The role of microvesicles in multiple myeloma progression.
Zarfati M; Katz T; Avivi I; Brenner B; Aharon A
Thromb Res; 2016 Apr; 140 Suppl 1():S193. PubMed ID: 27161734
[TBL] [Abstract][Full Text] [Related]
4. PML-RARa modulates the vascular signature of extracellular vesicles released by acute promyelocytic leukemia cells.
Fang Y; Garnier D; Lee TH; D'Asti E; Montermini L; Meehan B; Rak J
Angiogenesis; 2016 Jan; 19(1):25-38. PubMed ID: 26374632
[TBL] [Abstract][Full Text] [Related]
5. Extracellular vesicles from oral squamous carcinoma cells display pro- and anti-angiogenic properties.
de Andrade A; de Oliveira CE; Dourado MR; Macedo C; Winck FV; Paes Leme AF; Salo T; Coletta RD; de Almeida Freitas R; Galvão HC
Oral Dis; 2018 Jul; 24(5):725-731. PubMed ID: 28887832
[TBL] [Abstract][Full Text] [Related]
6. Intravenous Immunoglobulin G Suppresses Heat Shock Protein (HSP)-70 Expression and Enhances the Activity of HSP90 and Proteasome Inhibitors.
Jones RJ; Singh RK; Shirazi F; Wan J; Wang H; Wang X; Ha MJ; Baljevic M; Kuiatse I; Davis RE; Orlowski RZ
Front Immunol; 2020; 11():1816. PubMed ID: 32903557
[TBL] [Abstract][Full Text] [Related]
7. piRNA-823 delivered by multiple myeloma-derived extracellular vesicles promoted tumorigenesis through re-educating endothelial cells in the tumor environment.
Li B; Hong J; Hong M; Wang Y; Yu T; Zang S; Wu Q
Oncogene; 2019 Jun; 38(26):5227-5238. PubMed ID: 30890754
[TBL] [Abstract][Full Text] [Related]
8. Bortezomib mediates antiangiogenesis in multiple myeloma via direct and indirect effects on endothelial cells.
Roccaro AM; Hideshima T; Raje N; Kumar S; Ishitsuka K; Yasui H; Shiraishi N; Ribatti D; Nico B; Vacca A; Dammacco F; Richardson PG; Anderson KC
Cancer Res; 2006 Jan; 66(1):184-91. PubMed ID: 16397231
[TBL] [Abstract][Full Text] [Related]
9. Anti-tumor activity of the proteasome inhibitor BSc2118 against human multiple myeloma.
Zang M; Li Z; Liu L; Li F; Li X; Dai Y; Li W; Kuckelkorn U; Doeppner TR; Hermann DM; Zhou W; Qiu L; Jin F
Cancer Lett; 2015 Oct; 366(2):173-81. PubMed ID: 26116344
[TBL] [Abstract][Full Text] [Related]
10. MiR-195-5p and miR-205-5p in extracellular vesicles isolated from diabetic foot ulcer wound fluid decrease angiogenesis by inhibiting VEGFA expression.
Liu J; Wang J; Fu W; Wang X; Chen H; Wu X; Lao G; Wu Y; Hu M; Yang C; Yan L; Ren M
Aging (Albany NY); 2021 Aug; 13(15):19805-19821. PubMed ID: 34370714
[TBL] [Abstract][Full Text] [Related]
11. Extracellular vesicle-carried Jagged-1 inhibits HUVEC sprouting in a 3D microenvironment.
Tan E; Asada HH; Ge R
Angiogenesis; 2018 Aug; 21(3):571-580. PubMed ID: 29541959
[TBL] [Abstract][Full Text] [Related]
12. Egr-1 activation by cancer-derived extracellular vesicles promotes endothelial cell migration via ERK1/2 and JNK signaling pathways.
Yoon YJ; Kim DK; Yoon CM; Park J; Kim YK; Roh TY; Gho YS
PLoS One; 2014; 9(12):e115170. PubMed ID: 25502753
[TBL] [Abstract][Full Text] [Related]
13. Endocytic pathway inhibition attenuates extracellular vesicle-induced reduction of chemosensitivity to bortezomib in multiple myeloma cells.
Tu C; Du Z; Zhang H; Feng Y; Qi Y; Zheng Y; Liu J; Wang J
Theranostics; 2021; 11(5):2364-2380. PubMed ID: 33500730
[TBL] [Abstract][Full Text] [Related]
14. Curcusone D, a novel ubiquitin-proteasome pathway inhibitor via ROS-induced DUB inhibition, is synergistic with bortezomib against multiple myeloma cell growth.
Cao MN; Zhou YB; Gao AH; Cao JY; Gao LX; Sheng L; Xu L; Su MB; Cao XC; Han MM; Wang MK; Li J
Biochim Biophys Acta; 2014 Jun; 1840(6):2004-13. PubMed ID: 24534329
[TBL] [Abstract][Full Text] [Related]
15. Bortezomib inhibits the angiogenesis mediated by mesenchymal stem cells.
Wang X; Zhang Z; Yao C
Cancer Invest; 2012 Nov; 30(9):657-62. PubMed ID: 23013101
[TBL] [Abstract][Full Text] [Related]
16. Extracellular vesicles from blood of breast cancer women induce angiogenic processes in HUVECs.
Garcia-Hernandez A; Reyes-Uribe E; Arce-Salinas C; de la Cruz-Lopez KG; Manzo-Merino J; Guzman-Ortiz AL; Quezada H; Cortes-Reynosa P; Breton-Mora F; Elizalde-Acosta I; Thompson-Bonilla R; Salazar EP
Tissue Cell; 2022 Jun; 76():101814. PubMed ID: 35526310
[TBL] [Abstract][Full Text] [Related]
17. Synergistic effects of multiple myeloma cells and tumor-associated macrophages on vascular endothelial cells in vitro.
Sun M; Qiu S; Xiao Q; Wang T; Tian X; Chen C; Wang X; Han J; Zheng H; Shou Y; Chen K
Med Oncol; 2020 Oct; 37(11):99. PubMed ID: 33040185
[TBL] [Abstract][Full Text] [Related]
18. Annexin A1 May Induce Pancreatic Cancer Progression as a Key Player of Extracellular Vesicles Effects as Evidenced in the In Vitro MIA PaCa-2 Model System.
Pessolano E; Belvedere R; Bizzarro V; Franco P; Marco I; Porta A; Tosco A; Parente L; Perretti M; Petrella A
Int J Mol Sci; 2018 Dec; 19(12):. PubMed ID: 30518142
[TBL] [Abstract][Full Text] [Related]
19. CCR10/CCL27 crosstalk contributes to failure of proteasome-inhibitors in multiple myeloma.
Thangavadivel S; Zelle-Rieser C; Olivier A; Postert B; Untergasser G; Kern J; Brunner A; Gunsilius E; Biedermann R; Hajek R; Pour L; Willenbacher W; Greil R; Jöhrer K
Oncotarget; 2016 Nov; 7(48):78605-78618. PubMed ID: 27732933
[TBL] [Abstract][Full Text] [Related]
20. Combined inhibition of p97 and the proteasome causes lethal disruption of the secretory apparatus in multiple myeloma cells.
Auner HW; Moody AM; Ward TH; Kraus M; Milan E; May P; Chaidos A; Driessen C; Cenci S; Dazzi F; Rahemtulla A; Apperley JF; Karadimitris A; Dillon N
PLoS One; 2013; 8(9):e74415. PubMed ID: 24069311
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
